Polyrizon Ltd. (PLRZ) 10-Year Financial Performance & Capital Metrics

PLRZ • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutPolyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.Show more

Revenue $0
EBITDA -$1M -87.6%
Net Income -$2M -157.5%
EPS (Diluted) 0.50 +412.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -57.83% +94.5%
ROIC -65.43%
Debt/Equity -
Interest Coverage -434.00 -36.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 47.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM39.74%

EPS CAGR

10Y-

5Y-

3Y-

TTM-20.86%

ROCE

10Y Avg-3107.04%

5Y Avg-3107.04%

3Y Avg-581.39%

Latest-48.74%

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	1K	6K	5K	4K	118K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-1K	-6K	-5K	-4K	-118K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-5%	0.17%	0.2%	-28.5%
Operating Expenses+	71K	697K	895K	635K	1.3M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	33K	452K	548K	303K	768K
SG&A % of Revenue	-	-	-	-	-
Research & Development	38K	245K	347K	332K	534K
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-72K	-703K	-895K	-635K	-1.3M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-8.76%	-0.27%	0.29%	-1.05%
EBITDA+	-71K	-697K	-890K	-631K	-1.18M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-8.82%	-0.28%	0.29%	-0.88%
D&A (Non-Cash Add-back)	1K	6K	5K	4K	118K
EBIT	-73K	-709K	-777K	-635K	-1.54M
Net Interest Income+	0	-2K	-2K	-230K	-28K
Interest Income	0	0	0	0	0
Interest Expense	0	2K	2K	2K	3K
Other Income/Expense	-1K	-8K	116K	35K	-243K
Pretax Income+	-73K	-711K	-779K	-600K	-1.54M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-73K	-711K	-779K	-600K	-1.54M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-8.74%	-0.1%	0.23%	-1.57%
Net Income (Continuing)	-73K	-711K	-779K	-600K	-1.54M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.02	-0.17	-0.20	-0.16	0.50
EPS Growth %	-	-8.77%	-0.18%	0.2%	4.13%
EPS (Basic)	-0.02	-0.17	-0.20	-0.16	0.50
Diluted Shares Outstanding	4.19M	4.19M	1.31M	2.03M	2.99M
Basic Shares Outstanding	4.19M	4.19M	1.31M	2.03M	2.99M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	19K	544K	51K	54K	2.65M
Cash & Short-Term Investments	10K	523K	36K	41K	2.55M
Cash Only	10K	523K	36K	4K	2.55M
Short-Term Investments	0	0	0	37K	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	9K	21K	15K	13K	99K
Total Non-Current Assets+	5K	143K	495K	505K	2.89M
Property, Plant & Equipment	5K	18K	16K	12K	10K
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	2.88M
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	125K	479K	493K	0
Total Assets+	24K	687K	546K	559K	5.55M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	27.63%	-0.21%	0.02%	8.92%
Total Current Liabilities+	8K	690K	1.2M	502K	261K
Accounts Payable	0	0	0	0	0
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	200K	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	672K	1.16M	263K	45K
Current Ratio	2.38x	0.79x	0.04x	0.11x	10.16x
Quick Ratio	2.38x	0.79x	0.04x	0.11x	10.16x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	248K	0
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	248K	0
Total Liabilities	8K	690K	1.2M	750K	261K
Total Debt+	0	0	0	200K	0
Net Debt	-10K	-523K	-36K	196K	-2.55M
Debt / Equity	-	-	-	3.51x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-351.50x	-447.50x	-317.50x	-434.00x
Total Equity+	16K	-3K	-652K	57K	5.29M
Equity Growth %	-	-1.19%	-216.33%	1.09%	91.74%
Book Value per Share	0.00	-0.00	-0.50	0.03	1.77
Total Shareholders' Equity	16K	-3K	-652K	57K	5.29M
Common Stock	49K	326K	0	0	0
Retained Earnings	-1.43M	-2.14M	-2.92M	-3.52M	-5.07M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	-196K	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-73K	-492K	-1.13M	-537K	-1.15M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-5.74%	-1.3%	0.53%	-1.14%
Net Income	-73K	-711K	-779K	-600K	-1.54M
Depreciation & Amortization	1K	6K	5K	4K	118K
Stock-Based Compensation	0	184K	130K	100K	51K
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	0	-144K	-48K	250K
Working Capital Changes	-1K	29K	-344K	7K	-21K
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	0	0
Cash from Investing+	-6K	-19K	-3K	0	29K
Capital Expenditures	-6K	-19K	-3K	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	89K	1.02M	648K	505K	3.67M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	-648K	0	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-79K	-511K	-1.14M	-537K	-1.15M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-5.47%	-1.22%	0.53%	-1.14%
FCF per Share	-0.02	-0.12	-0.87	-0.26	-0.38
FCF Conversion (FCF/Net Income)	1.00x	0.69x	1.45x	0.90x	0.74x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-456.25%	-10938.46%	-	-1052.63%	-57.83%
Return on Invested Capital (ROIC)	-	-	-	-	-65.43%
Debt / Equity	-	-	-	3.51x	-
Interest Coverage	-	-351.50x	-447.50x	-317.50x	-434.00x
FCF Conversion	1.00x	0.69x	1.45x	0.90x	0.74x

Frequently Asked Questions

Valuation & Price

Polyrizon Ltd. (PLRZ) has a price-to-earnings (P/E) ratio of 31.1x. This suggests investors expect higher future growth.

Growth & Financials

Polyrizon Ltd. (PLRZ) grew revenue by 0.0% over the past year. Growth has been modest.

Polyrizon Ltd. (PLRZ) reported a net loss of $1.0M for fiscal year 2024.

Dividend & Returns

Polyrizon Ltd. (PLRZ) has a return on equity (ROE) of -57.8%. Negative ROE indicates the company is unprofitable.

Polyrizon Ltd. (PLRZ) had negative free cash flow of $0.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener